Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 22695536)

1.

Methylation signature of lymph node metastases in breast cancer patients.

Barekati Z, Radpour R, Lu Q, Bitzer J, Zheng H, Toniolo P, Lenner P, Zhong XY.

BMC Cancer. 2012 Jun 13;12:244. doi: 10.1186/1471-2407-12-244.

2.

Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array.

Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY.

Oncogene. 2009 Aug 20;28(33):2969-78. doi: 10.1038/onc.2009.149. Epub 2009 Jun 8.

PMID:
19503099
3.

Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.

Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, Daoud J, Frikha M, Jlidi R, Gargouri A, Mokdad-Gargouri R.

J Cancer Res Clin Oncol. 2010 Feb;136(2):203-10. doi: 10.1007/s00432-009-0649-6. Epub 2009 Aug 6.

PMID:
19657672
4.

Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.

Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, Lønning PE, Solvang H, Børresen-Dale AL, Tost J, Kristensen VN.

BMC Cancer. 2013 Oct 5;13:456. doi: 10.1186/1471-2407-13-456.

5.

Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.

Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.

Breast Cancer Res. 2008;10(3):R46. doi: 10.1186/bcr2098. Epub 2008 May 16.

6.

CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.

Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW.

BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247.

7.

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.

D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.

Breast Cancer Res Treat. 2007 Mar;101(3):279-84. Epub 2006 Jul 12.

PMID:
16835704
8.

Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer.

Radpour R, Barekati Z, Kohler C, Lv Q, Bürki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY.

PLoS One. 2011 Jan 24;6(1):e16080. doi: 10.1371/journal.pone.0016080.

10.

Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.

Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, Vooijs M, van Diest PJ.

Ann Oncol. 2008 Nov;19(11):1870-4. doi: 10.1093/annonc/mdn409. Epub 2008 Jul 22.

11.

Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.

Rivenbark AG, Livasy CA, Boyd CE, Keppler D, Coleman WB.

Exp Mol Pathol. 2007 Oct;83(2):188-97. Epub 2007 Apr 18.

12.

Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.

Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B.

Clin Cancer Res. 2005 Mar 15;11(6):2156-62.

13.

Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?

Falck AK, Fernö M, Bendahl PO, Rydén L.

World J Surg. 2010 Jul;34(7):1434-41. doi: 10.1007/s00268-010-0499-z.

PMID:
20213203
14.

Correlation between CpG methylation profiles and hormone receptor status in breast cancers.

Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y.

Breast Cancer Res. 2007;9(4):R57.

15.

Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer.

Wee EJ, Peters K, Nair SS, Hulf T, Stein S, Wagner S, Bailey P, Lee SY, Qu WJ, Brewster B, French JD, Dobrovic A, Francis GD, Clark SJ, Brown MA.

Oncogene. 2012 Sep 20;31(38):4182-95. doi: 10.1038/onc.2011.584. Epub 2012 Jan 9.

16.

Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer.

Jung EJ, Kim IS, Lee EY, Kang JE, Lee SM, Kim DC, Kim JY, Park ST.

Ann Lab Med. 2013 Nov;33(6):431-40. doi: 10.3343/alm.2013.33.6.431. Epub 2013 Oct 17.

17.

Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.

Barekati Z, Radpour R, Kohler C, Zhang B, Toniolo P, Lenner P, Lv Q, Zheng H, Zhong XY.

Hum Mol Genet. 2010 Aug 1;19(15):2936-46. doi: 10.1093/hmg/ddq199. Epub 2010 May 12.

18.

Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.

Sturgeon SR, Balasubramanian R, Schairer C, Muss HB, Ziegler RG, Arcaro KF.

Epigenetics. 2012 Nov;7(11):1258-67. doi: 10.4161/epi.22220. Epub 2012 Sep 17.

19.

A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.

Woo SU, Bae JW, Kim CH, Lee JB, Koo BW.

Ann Surg Oncol. 2008 Jan;15(1):281-5. Epub 2007 Sep 1.

PMID:
17763975
20.

Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.

Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER, Latif F.

Cancer Res. 2011 Apr 15;71(8):2988-99. doi: 10.1158/0008-5472.CAN-10-4026. Epub 2011 Mar 1. Erratum in: Cancer Res. 2012 Jun 15;72(12):3115.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk